# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Friedrich Nietzsche (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI019-SYN-TD
- Date: 1881-07-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Konrad Ellison-Mbatha, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing primary care for frequent disabling headaches with nausea and light sensitivity: headache history and red-flag screen, a headache diary, disability and mood screening, the daily combination tablets, MRI and syphilis serology, his eyes and his sleep. **S**

## Objective

MIDAS 1, work days missed: 14 d; MIDAS 2, work days at half productivity or less: 22 d; MIDAS 3, household work days missed: 8 d; MIDAS 4, household days at half productivity or less: 12 d; MIDAS 5, family, social or leisure days missed: 18 d; PHQ-9: 7; GAD-7: 6; AUDIT-C: 1. All results are synthetic.

BP 118/76 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 66 kg; BMI 21.8 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Frequent disabling headaches on about 20 days a month, with nausea, vomiting and light sensitivity, mostly right-sided, since childhood and more frequent over the past year, with a combination headache tablet containing butalbital taken on about 16 days a month; under evaluation with a headache diary, MRI, syphilis serology and a headache medicine consultation; High myopia in both eyes, much worse in the right eye, since early childhood, with long-standing poor vision in the right eye and unequal pupils; comprehensive eye examination booked; Chronic insomnia, with difficulty falling asleep and early waking, worse on headache nights; no sleep medicine at intake. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, one or two tablets as needed for headache, taken on about 16 days a month, up to four tablets a day (prescribed abroad) **S**
- Continued without change: Ibuprofen 200 mg oral tablet, two tablets as needed for headache on days without the combination tablets, about 4 days a month (over the counter) **S**

## Plan

- Diagnosis: a structured headache history, a red-flag screen (SNNOOP10) at every visit, a 14-day diary of headache days, attack features, triggers and every dose of acute medicine, and ICHD-3 criteria; MRI of the brain with and without contrast because the headaches have become more frequent over the past year, are strongly right-sided, and come with long-standing unequal pupils and a very poor right eye; treponemal and nontreponemal syphilis serology because of past gonorrhea, unequal pupils and poor vision. Guideline: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013); Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) **S**
- Neurology (headache medicine) consultation to confirm the diagnosis and advise on withdrawal of the overused tablets and on preventive treatment. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024); European Academy of Neurology guideline on the management of medication-overuse headache (2020) **S**
- Medication overuse at intake: explain how frequent combination tablets can keep headaches going; count every tablet and acute-medicine day in the diary; take no more than now and never more than four combination tablets a day until the consultation; no new sedatives or sleeping tablets. Guideline: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); European Academy of Neurology guideline on the management of medication-overuse headache (2020) **S**
- Comprehensive eye examination for high myopia: refraction, pupils, pressure, a dilated fundus examination for myopic degeneration, retinal breaks and lattice, and macular OCT; correction of the large difference between the eyes; the warning signs of retinal detachment and an Amsler grid; dilated examination every year. Guideline: Refractive Errors Preferred Practice Pattern (2023); Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (2025); Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern (2026) **S**
- Sleep: cognitive behavioral therapy for insomnia through the clinic's behavioral sleep program, a fixed rising time, a wind-down hour, and no sedative sleeping tablets. Guideline: Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021) **S**
- Mood: PHQ-9 and GAD-7 at intake and at about two to three months, with direct questions about hopelessness and self-harm at each visit; a safety assessment if a score or answer calls for one. Guideline: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Reading, writing and walking: good light, large print and an enlarged screen, breaks every 30 minutes, voice dictation for long passages, sunglasses and a brimmed hat for glare, and his daily walks kept as a protected part of the plan. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Refractive Errors Preferred Practice Pattern (2023) **S**
